CBP/p300-IN-22

CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4 (1) . CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions[1].

Product Specifications

UNSPSC

12352005

Target

Epigenetic Reader Domain; Histone Acetyltransferase; NF-κB

Related Pathways

Epigenetics; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

CC1=CC2=C(NC(C3=CC(C4=NN(C)C=C4)=CC(NC(C5=CC=CO5)=O)=C3)=O)C=CC=C2N=N1

Molecular Formula

C25H20N6O3

Molecular Weight

452.46

References & Citations

[1]Gosselé KA, et al. Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation. JACS Au. 2025 Jun 5;5 (6) :2491-2499.